Clinical Drug Investigation

, Volume 32, Issue 2, pp 99–110

Monthly Administration of a Continuous Erythropoietin Receptor Activator Provides Efficient Haemoglobin Control in Non-Dialysis Patients during Routine Clinical Practice

Results from the Non-Interventional, Single-Cohort, Multicentre, SUPRA Study
  • Stefan Heidenreich
  • Frank Leistikow
  • Stefan Zinn
  • Jörg Baumann
  • Andreas Atzeni
  • Vitomir Bajeski
  • Jörn Dietzmann
  • Gert-Peter Dragoun
Original Research Article

Abstract

Background: The continuous erythropoietin receptor activator (C.E.R.A.) has a long half-life, a relatively low binding affinity for the erythropoiesis receptor and low systemic clearance. These characteristics permit once-monthly dosing, which could reduce staffing requirements and be advantageous for patients. However, outcomes observed during controlled trials of C.E.R.A. have not been assessed under everyday clinical conditions in which physicians make all therapeutic decisions based on their own experience, rather than according to a pre-defined protocol.

Objective: This study aimed to assess whether the efficacy and safety of C.E.R.A. reported during controlled trials are reproducible under routine clinical conditions.

Methods: This was a non-interventional, single-cohort, multicentre study carried out in 92 specialist nephrology clinics and private practices in Germany. The study included patients with non-dialysis chronic kidney disease and anaemia, with or without current erythropoiesis stimulating agent (ESA) therapy. C.E.R.A. initiation and dosing was at the discretion of the physician. The primary efficacy variable was the proportion of patients for whom all measured haemoglobin (Hb) values during months 7–9 were within the range 11–12g/dL (‘responders’).

Results: 335 patients received ≥1 dose of C.E.R.A.; 150 had previously received ESA therapy. The mean number of doses was 7.6 per patient over a mean follow-up of 7.9 months. Mean ± SD Hb was 10.7 ± 1.1 g/dL at baseline and 11.3 ± 1.1 g/dL at the final visit (efficacy population, n = 205). The primary endpoint, all measured Hb values during months 7–9 within the range 11–12 g/dL, was achieved by 19.0% (39/205) of patients, increasing to 41.5% for Hb 11–13 g/dL, 42.0% for 10–12 g/dL and 76.6% for Hb ≥10g/dL. Hb fluctuation during months 7–9 was ≤1 g/dL in 185/205 patients (90.2%). C.E.R.A. was well tolerated without novel safety concerns.

Conclusion: Hb levels remained stable during routine use of C.E.R.A. in an unselected population of non-dialysis chronic kidney disease patients with anaemia. C.E.R.A. was administered approximately monthly compared with 3–7 doses per month on previous ESA therapy.

References

  1. 1.
    McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20(9): 1501–10PubMedCrossRefGoogle Scholar
  2. 2.
    Valderrábano F, Hörl WH, Macdougall IC, et al. PREdialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18(1): 89–100PubMedCrossRefGoogle Scholar
  3. 3.
    Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4(1): 33–8PubMedCrossRefGoogle Scholar
  4. 4.
    Fishbane S. Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 2008; 4(4): 401–10PubMedCrossRefGoogle Scholar
  5. 5.
    Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69(3): 560–4PubMedCrossRefGoogle Scholar
  6. 6.
    Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19(1): 121–32PubMedCrossRefGoogle Scholar
  7. 7.
    KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50(3): 471–30CrossRefGoogle Scholar
  8. 8.
    Locatelli F, Covic A, Eckardt KU, et al. ERA-EDTA ERBP Advisory Board Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24(2): 348–54PubMedCrossRefGoogle Scholar
  9. 9.
    Locatelli F, Covic A, Macdougall IC, et al., ORAMA Study Group. ORAMA: a study to investigate EBPG impact on renal anaemia. Design and baseline data. J Nephrol 2008; 21(4): 592–603PubMedGoogle Scholar
  10. 10.
    Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008; 13(4): 393–404PubMedCrossRefGoogle Scholar
  11. 11.
    Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68(3): 1337–43PubMedCrossRefGoogle Scholar
  12. 12.
    Yang W, Israni RK, Brunelli SM, et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18(12): 3164–70PubMedCrossRefGoogle Scholar
  13. 13.
    Rossert J, Gassmann-Mayer C, Frei D, et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22(3): 794–800PubMedCrossRefGoogle Scholar
  14. 14.
    De Cock E, Van Bellinghen L, Standaert B. Assessing provider time for anaemia management of dialysis patients using time and motion methods: a multi-centre observational study in Europe [abstract]. Value Health 2002; 5: 581CrossRefGoogle Scholar
  15. 15.
    Wish JB, Coyne DW. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 2007; 82(11): 1371–80PubMedCrossRefGoogle Scholar
  16. 16.
    Macdougall IC, Robson R, Opatrna S, et al. Pharmaco-kinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1(6): 1211–5PubMedCrossRefGoogle Scholar
  17. 17.
    Locatelli F, Villa G, de Francisco ALM, et al., BA16286 study investigators. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin 2007; 23(5): 969–79PubMedCrossRefGoogle Scholar
  18. 18.
    Levin NW, Fishbane S, Cañedo FV, et al., MAXIMA Study Investigators. Intravenous methoxy polyethylene glycolepoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370(9596): 1415–21PubMedCrossRefGoogle Scholar
  19. 19.
    Sulowicz W, Locatelli F, Ryckelynck JP, et al., PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2(4): 637–46PubMedCrossRefGoogle Scholar
  20. 20.
    Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant 2011. Epub ahead of printGoogle Scholar
  21. 21.
    Macdougall IC, Walker R, Provenzano R, et al., ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3(2): 337–47PubMedCrossRefGoogle Scholar
  22. 22.
    Kessler M, Martinez-Castelao A, Siamopoulos KC, et al. C.E.R.A. once every 4 weeks in patients with chronic disease not on dialysis: the ARCTOS extension study. Hemodial Int 2010; 14(2): 233–9PubMedCrossRefGoogle Scholar
  23. 23.
    Drueke TB, Locatelli F, Clyne N, et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006; 335(20): 2071–84CrossRefGoogle Scholar
  24. 24.
    Singh AK, Szczech L, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006; 335(20): 2085–98CrossRefGoogle Scholar
  25. 25.
    Hörl WH. A need for an individualized approach to endstage renal disease patients. Nephrol Dial Transplant 2002; 17Suppl. 6: 17–21PubMedCrossRefGoogle Scholar
  26. 26.
    Locatelli F, Aljama P, Canaud B, et al., Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25(9): 2846–50PubMedCrossRefGoogle Scholar
  27. 27.
    Macdougall IC. Individualizing target haemoglobin concentrations: tailoring treatment for renal anaemia. Nephrol Dial Transplant 2001; 6Suppl. 7: 9–14CrossRefGoogle Scholar
  28. 28.
    Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50(6): 989–1000PubMedCrossRefGoogle Scholar
  29. 29.
    Spinowitz B, Coyne DW, Lok CE, et al., RUBRA Study Investigators. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Am J Nephrology 2008; 28(2): 280–9CrossRefGoogle Scholar
  30. 30.
    Canaud B, Mingardi G, Braun J, et al., STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008; 23(11): 3654–61PubMedCrossRefGoogle Scholar
  31. 31.
    Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40(1): 110–8PubMedCrossRefGoogle Scholar
  32. 32.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRefGoogle Scholar
  33. 33.
    Eckardt KU, Berns JS, Rocco MV, et al. Definition and classification of CKD: the debate should be about patient prognosis. A position statement from KDOQI and KDIGO. Am J Kidney Dis 2009; 53(6): 915–20PubMedCrossRefGoogle Scholar
  34. 34.
    Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin treated hemodialysis patients. Kidney Int 2003; 64(4): 1514–21PubMedCrossRefGoogle Scholar
  35. 35.
    Hörl WH. Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002; 17Suppl. 11: 35–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Stefan Heidenreich
    • 1
  • Frank Leistikow
    • 2
  • Stefan Zinn
    • 3
  • Jörg Baumann
    • 4
  • Andreas Atzeni
    • 5
  • Vitomir Bajeski
    • 6
  • Jörn Dietzmann
    • 7
  • Gert-Peter Dragoun
    • 8
  1. 1.Praxis für Nieren- und HochdruckkrankheitenAachenGermany
  2. 2.Dialysezentrum und SchwerpunktpraxisMannheim-KäfertalGermany
  3. 3.Nephrologische GemeinschaftspraxisAlsfeldGermany
  4. 4.PHV DialysezentrumHerfordGermany
  5. 5.DialysepraxisOsnabrückGermany
  6. 6.Bielefelder DialysezentrumBielefeldGermany
  7. 7.Praxis für Innere Medizin und NephrologieBernburgGermany
  8. 8.KfH NierenzentrumAschaffenburgGermany

Personalised recommendations